Different Way

The point of personalized medicine, as the mantra goes, is to bring the right treatment to the right patient at the right time. But getting such tailored therapies approved may mean that how clinical trials assessing their efficacy and safety are conducted needs to be re-thought, writes Susan Young at Technology Review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Pair of Them

This Week in Nature

This Week in PLOS

New Treatments to Try

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.